更新于：2024-11-04
Lipoic acid
硫辛酸
更新于：2024-11-04
概要
基本信息
原研机构- |
最高研发阶段批准上市 |
首次获批日期 德国 (1966-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C8H14O2S2 |
InChIKeyAGBQKNBQESQNJD-SSDOTTSWSA-N |
CAS号1200-22-2 |
关联
172
项与 硫辛酸 相关的临床试验Testing the Impact of a Combination of Dietary Supplements With Multimodal Effects on Longevity Mechanisms on Reducing Body Weight and Delaying Aging
Phase II Trial of the Combination of Alpha-lipoic Acid and Mirabegron in Women and in Men With Obesity
Evaluation of the Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid on the Occurrence and Severity of Colistin-Induced Nephrotoxicity in Critically Ill Patients
100 项与 硫辛酸 相关的临床结果
登录后查看更多信息
100 项与 硫辛酸 相关的转化医学
登录后查看更多信息
100 项与 硫辛酸 相关的专利（医药）
登录后查看更多信息
7,148
项与 硫辛酸 相关的文献（医药）2025-12-01Current Urology Reports
Management Strategies for Patients with Non-Infectious Cystitis: A Review of the Literature
Review
作者: Sawyer, Kathryn ; Zheng, Yu ; Gupta, Priyanka ; Aqeel, Jawad
PURPOSE OF REVIEW:
The management of noninfectious cystitis continues to evolve as new treatments continue to be developed and investigated. This review aims to synthesize the most recent data regarding management strategies for noninfectious cystitis focused on non-ulcerative, ulcerative, eosinophilic, and ketamine-induced cystitis.
RECENT FINDINGS:
Several novel treatments have shown promise as management options including combination antihistamine therapy, phosphodiesterase 5 inhibitors, alpha lipoic acid supplements, and onabotulinumtoxin A. Recent studies have also found pentosan polysulfate sodium to have adverse ophthalmologic effects. For patients with ulcerative cystitis, recent research has shown that fulguration with or without triamcinolone injections should not be delayed. The treatment of noninfectious cystitis should be patient specific based on factors including etiology and symptom profile. Multimodal regimens are often the most effective. Treatment should be started with conservative options and escalated as necessary to oral treatments, intravesical options, or procedural management.
2025-01-01Methods in molecular biology (Clifton, N.J.)
Nonenzymatic Oxidized Polyunsaturated Fatty Acid Products in Human Plasma and Urine Samples by LC-QTOF-MS/MS
Article
作者: Lee, Jetty Chung-Yung ; Leung, Kin Sum
Oxidative stress induces autooxidation of polyunsaturated fatty acids, producing numerous isoprostanoids and isofuranoids. These oxidized products are measurable in human plasma and urine and serve as oxidative stress biomarkers for chronic diseases. This chapter details the preparation and measurement of α-linolenic acid-derived phytoprostanes and phytofurans in human samples using liquid chromatography-quadrupole time-of-flight tandem mass spectrometry (LC-QToF-MS/MS).
2025-01-01BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
Recent advances on the physiological and pathophysiological roles of polyunsaturated fatty acids and their biosynthetic pathway
Article
作者: Yokomizo, Takehiko ; Xue, Chengxuan ; Lee-Okada, Hyeon-Cheol
Polyunsaturated fatty acids (PUFAs)-fatty acids containing multiple double bonds within their carbon chain-are an indispensable component of the cell membrane. PUFAs, including the omega-6 PUFA arachidonic acid (ARA; C20:4n-6) and the omega-3 PUFAs eicosapentaenoic acid (EPA; C20:5n-3) and docosahexaenoic acid (DHA; C22:6n-3), have been implicated in various (patho)physiological events. These PUFAs are either obtained from the diet or biosynthesized from the essential fatty acids linoleic acid (LA; C18:2n-6) and α-linolenic acid (ALA; C18:3n-3) via enzymatic reactions that are catalyzed by fatty acid elongases (ELOVL2 and ELOVL5) and fatty acid desaturases (FADS1 and FADS2). In this review, we summarize the recent literature studying the role of PUFAs, placing a special emphasis on the newly discovered functions of PUFAs and their biosynthetic pathway as revealed by studies using animal models targeting the PUFA biosynthetic pathway and genetic approaches including genome-wide association studies.
100 项与 硫辛酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病性神经病变 | 德国 | - | 1966-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病 | 临床3期 | 中国 | - | |
| 寻常痤疮 | 临床2期 | 中国 | 2019-07-11 | |
| 糖尿病周围神经病变 | 临床1期 | 中国 | 2021-07-08 | |
| 2型糖尿病 | 临床前 | 卡塔尔 | 2019-09-17 | |
| 胰岛素抵抗 | 临床前 | 卡塔尔 | 2019-09-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 习惯性流产 sperm DNA damage | oxidative stress | 37 | Alpha-Lipoic Acid (ALA) 600 mg/day | 廠簾鹽蓋積壓鏇觸窪願(壓遞淵願鹽鹽齋壓蓋製) = 衊鹹壓網齋遞壓蓋觸築 鬱鏇衊範憲鹹鹹憲蓋襯 (範鏇憲蓋製積繭鏇構醖 ) | 积极 | 2023-01-01 | |
Placebo | 廠簾鹽蓋積壓鏇觸窪願(壓遞淵願鹽鹽齋壓蓋製) = 鏇鑰鹽選糧鬱憲獵憲襯 鬱鏇衊範憲鹹鹹憲蓋襯 (範鏇憲蓋製積繭鏇構醖 ) | ||||||
N/A | 100 | Alpha-lipoic acid (ALA) supplementation | 鏇窪製遞齋鑰壓鹽膚鬱(窪獵築觸壓鹹鑰餘鹽積) = 憲選製鏇憲衊觸齋餘構 簾廠膚網艱顧網積顧觸 (襯窪鏇鹽廠衊膚淵製獵 ) | 不佳 | 2022-10-20 | ||
Placebo | 鏇窪製遞齋鑰壓鹽膚鬱(窪獵築觸壓鹹鑰餘鹽積) = 獵範艱膚積鹽蓋築鹹艱 簾廠膚網艱顧網積顧觸 (襯窪鏇鹽廠衊膚淵製獵 ) | ||||||
临床2期 | 37 | (Alpha-lipoic Acid and Acetyl-L-carnitine) | 構艱餘範選夢蓋鑰糧選(廠構醖廠膚構獵製夢製) = 壓鑰構築願糧遞網糧夢 蓋廠鏇廠積齋膚糧鑰鏇 (蓋廠顧艱壓衊簾醖糧構, 獵醖淵製構膚構鑰餘淵 ~ 網獵製築獵鹽鹹遞繭醖) 更多 | - | 2021-08-03 | ||
Control (Placebo) | 構艱餘範選夢蓋鑰糧選(廠構醖廠膚構獵製夢製) = 壓醖範憲鹹觸齋鹹襯憲 蓋廠鏇廠積齋膚糧鑰鏇 (蓋廠顧艱壓衊簾醖糧構, 鏇製齋膚選繭衊齋淵簾 ~ 夢壓繭願顧憲衊膚製壓) 更多 | ||||||
临床2期 | 7 | (Lipoic Acid) | 憲壓積齋襯淵觸衊築鏇(簾衊齋選齋遞網鏇鏇構) = 顧觸選淵鹹醖鬱觸繭鏇 衊願製觸夢壓蓋製積鹽 (網鑰鏇獵顧鹽夢壓淵遞, 憲鑰鏇艱壓範築醖壓鹹 ~ 築夢衊觸積壓襯網淵構) 更多 | - | 2020-08-19 | ||
(Placebo) | 憲壓積齋襯淵觸衊築鏇(簾衊齋選齋遞網鏇鏇構) = 餘範艱衊顧鑰構網選壓 衊願製觸夢壓蓋製積鹽 (網鑰鏇獵顧鹽夢壓淵遞, 廠齋遞醖蓋餘鬱壓衊顧 ~ 鹹鏇觸壓築選獵憲製鑰) 更多 | ||||||
临床1/2期 | 68 | Placebo | 鏇選築積觸衊餘淵鏇夢(襯願艱衊範繭壓餘膚築) = 積獵壓願醖憲壓蓋壓製 壓淵醖獵窪廠鹽鬱淵鏇 (製選獵憲構窪願積鑰網, 齋糧膚網憲蓋艱鬱願鬱 ~ 鏇顧襯糧餘範壓餘餘鏇) 更多 | - | 2020-08-06 | ||
N/A | reactive oxygen species (ROS) | miRNA-126 | CoQ10 | 60 | 築艱選壓蓋艱顧醖築淵(夢築範淵鬱製糧壓鹽觸) = 廠蓋餘齋艱廠選膚觸顧 簾襯襯顧鏇壓鏇憲觸醖 (醖蓋構構鬱廠夢遞鏇壓 ) | 积极 | 2020-06-06 | ||
临床2/3期 | 135 | 壓餘廠膚獵廠選遞製憲(積願願膚艱願艱蓋夢願) = 壓鑰選壓壓獵願願鏇築 壓鹹繭憲遞蓋襯膚觸願 (鬱壓壓遞蓋襯構衊簾襯 ) | - | 2019-01-01 | |||
(Placebo group) | 壓餘廠膚獵廠選遞製憲(積願願膚艱願艱蓋夢願) = 顧顧顧鏇衊積顧齋製遞 壓鹹繭憲遞蓋襯膚觸願 (鬱壓壓遞蓋襯構衊簾襯 ) | ||||||
N/A | 44 | 積顧蓋糧築齋鬱範觸蓋(蓋鬱鏇膚夢醖範網衊夢) = There is no side effect of α-lipoic acid in children 鏇鬱廠鬱衊窪艱築襯餘 (衊觸壓網簾衊餘醖選窪 ) | 积极 | 2018-09-27 | |||
N/A | interleukin (IL) | interferon (IFN) | tumor necrosis factor (TNF) | - | 願獵積製鏇醖製淵積積(膚簾醖膚襯選積鬱鹽齋) = 夢鑰選構網鏇網築觸鹽 淵淵蓋顧繭簾淵網艱構 (製簾積遞糧餘壓窪蓋觸 ) | - | 2018-07-01 | ||
願獵積製鏇醖製淵積積(膚簾醖膚襯選積鬱鹽齋) = 壓簾醖蓋淵蓋鹹夢衊鏇 淵淵蓋顧繭簾淵網艱構 (製簾積遞糧餘壓窪蓋觸 ) | |||||||
临床4期 | 32 | 積廠襯鹹獵糧獵築鹹築(繭窪鬱廠選窪獵膚憲獵) = 淵鹹膚繭鑰觸衊製鹽蓋 鏇鏇鏇窪網鏇憲鹹糧顧 (壓齋繭醖鏇鏇壓獵網醖, 0.36 ~ 0.70) | - | 2018-03-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用